Zhejiang Pharmaceutical: XC2309 Injection approved for drug clinical trial notification.

Zhejiang Pharmaceuticals announced that the company recently received the "Notice of Approval for Clinical Trial of XC2309 Injection" issued by the National Medical Products Administration. The application for clinical trials of XC2309 injection meets the relevant requirements for drug registration, and it is approved to conduct clinical trials of this product. This medicine is used for gastrointestinal ulcer bleeding caused by various conditions. As of now, the company has accumulated research and development costs of 83.96 million yuan for the XC2309 project.